Purpose
The molecular imaging of tumour neoangiogenesis currently represents a major field of research for the diagnostic and treatment
strategy of solid tumours. Endothelial cells from tumour neovessels overexpress the αvβ3 integrin, which selectively binds to Arg-Gly-Asp (RGD)-containing peptides. We evaluated the potential of the novel radiotracer
99mTc-RAFT-RGD for the non-invasive molecular imaging of αvβ3 integrin expression in mice models of tumour development.
Methods
99mTc-RAFT-RGD, 99mTc-cRGD (specific control) and 99mTc-RAFT-RAD (non-specific control) were injected intravenously to mice bearing B16F0 or TS/A-pc tumours. In vivo whole-body
tomographic imaging and post-mortem biodistribution studies were performed 60 min following tracer injection. Adjacent tumour
slices were used to compare the localisation of neovessels from immunostaining and the pattern of 99mTc-RAFT-RGD uptake from autoradiographic ex vivo imaging.
Results
Biodistribution studies indicated that 99mTc-RAFT-RGD tumour uptake was significantly higher than that of 99mTc-RAFT-RAD in B16F0 (2.4±0.5 vs 1.0±0.1%ID/g, respectively) and in TS/A-pc tumours (2.7±0.8 vs 0.7±0.1%ID/g, respectively).
Immunohistochemical and autoradiographic studies indicated that 99mTc-RAFT-RGD intratumoural uptake preferentially occurred in angiogenic areas. Tomographic imaging allowed tumour visualisation
following injection of 99mTc-RAFT-RGD and 99mTc-cRGD with similar tumour-to-contralateral muscle (T/CM) ratios in B16F0 and in TS/A-pc tumours whereas 99mTc-RAFT-RAD T/CM ratios did not allow tumour imaging. In accordance with the higher level of αvβ3 integrin expression on TS/A-pc tumours than on B16F0 tumours as determined from western blot and immunoprecipitation analyses,
the 99mTc-RAFT-RGD T/CM ratio was significantly higher in TS/A-pc than in B16F0 tumours.
Conclusion
99mTc-RAFT-RGD allowed the in vivo imaging of αvβ3 integrin tumour expression.
Keywords Molecular imaging - Angiogenesis - Tumour imaging - Radiopharmaceuticals -
99mTc-RAFT-RGD